Navigation Links
Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance
Date:4/24/2008

are difficult to forecast accurately for future periods. We believe that the use of non-GAAP measures helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the company's performance, especially when comparing such results to previous periods or forecasts.

For example:

We exclude costs and tax effects associated with restructuring activities, such as reducing overhead and consolidating facilities in connection with the Fisher merger. We believe that the costs related to these restructuring activities are not indicative of our normal operating costs.

We exclude certain acquisition-related costs, including charges for the sale of inventories revalued at the date of acquisition and professional fees related to the merger with Fisher. We exclude these costs because we do not believe they are indicative of our normal operating costs.

We exclude the expense and tax effects associated with the amortization of acquisition-related intangible assets because a significant portion of the purchase price for acquisitions may be allocated to intangible assets that have lives of 5 to 20 years. Our adjusted EPS estimate for 2008 excludes approximately $.89 of expense for the amortization of acquisition-related intangible assets for acquisitions completed through the first quarter of 2008. Exclusion of the amortization expense allows comparisons of operating results that are consistent over time for both our newly acquired and long-held businesses and with both acquisitive and non-acquisitive peer companies.

We also exclude certain gains/losses and related tax effects, benefits from tax credit carryforwards and the impact of significant tax audits or events (such as the one-time effect on deferred tax balances of enacted changes in tax rates), which are either isolated or cannot be expected to occur again with any regularity or predictability and that w
'/>"/>

SOURCE Thermo Fisher Scientific Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Thermo Fisher Scientific to Present at Upcoming Investor Conferences
2. Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, April 24, 2008
3. Thermo Fisher Scientific Unveils New Laboratory Technologies at Analytica 2008
4. Boston College, MIT researchers achieve dramatic increase in thermoelectric efficiency
5. ThermoGenesis Names Dr. Mahendra Rao to Board of Directors
6. ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health
7. Thermo Fisher Scientific to Webcast Press Conference at PITTCON 2008
8. ThermoGenesis Corp. Announces Voluntary Recall of Selected Lots of AXP Bag Sets
9. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
10. Thermo Fisher Scientific Reports Record 2007 Fourth Quarter Revenues and Operating Performance; Provides Guidance for 2008
11. Research Using Thermo Fisher Scientific RNA-Interference Technology Unveils Potential New Targets for HIV Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ... an optimized Erk inhibitor molecule for development, thus ... a new class of potential cancer therapies. ... target for therapeutic intervention in cancer. Recently approved ... for B-Raf and Mek inhibitors. Erk inhibitors may ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... PRC Clinical, a Silicon Valley-based CRO specializing in Clinical Trial Management. CSSi ... patient recruitment services. The core expertise of PRC Clinical is focused on Clinical ...
(Date:7/29/2015)... ... July 29, 2015 , ... Costello served as Lead ... to protect the Orange County, Texas area from future storm surge flooding, such ... in determining several potential levee alignment alternatives for providing protection, Costello also balanced socio-economic ...
(Date:7/29/2015)... ... July 29, 2015 , ... Asymmetrex, ... good progress in evaluating the full range of capabilities of its unique cache ... stem cells perform the day-to-day renewal and repair of normal tissues and organs. ...
Breaking Biology Technology:Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Preventing Storm Surge Flooding in Houston 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4
... Texas, Dec. 21 Lexicon,Pharmaceuticals, Inc. (Nasdaq: ... investigational new drug (IND) application to the U.S. ... drug candidate for managing,gastrointestinal symptoms associated with carcinoid ... is planned as a double-blind, randomized,placebo-controlled, ascending single-dose ...
... MALVERN, Pa., Dec. 21 Solstice Neurosciences, Inc.,("Solstice") ... President and,Chief Executive Officer. He will also continue ... Mr. Smith brings unique specialty pharmaceutical industry ... in providing guidance,leadership, and strategies for growth as ...
... ROCK, Colo., Dec. 20 AspenBio Pharma,Inc. (Nasdaq: ... to the,development of novel drugs and diagnostics for ... into securities purchase agreements in,connection with a private ... Under the terms of the agreement, AspenBio will ...
Cached Biology Technology:Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome 2Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome 3Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc. 2AspenBio Pharma Announces $18 Million Private Placement of Common Stock 2AspenBio Pharma Announces $18 Million Private Placement of Common Stock 3
(Date:7/21/2015)... -- Today, ZTE announced its Android smartphone Axon, featuring ... revenues in 2015 that relate to sales of FPC1025 for this ... 2,200 MSEK for 2015. Jörgen Lantto, CEO of FPC, ... China and we are proud that ... Axon , its first ...
(Date:7/20/2015)...  Acuity Market Intelligence,s latest research "The Global ... and Privacy" forecasts that between 2014 and 2020 ... downloaded to smart mobile devices by 2.2 billion ... projected to generate more than $67.9 billion in ... period.    "Biometrics is at the ...
(Date:7/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the fourth quarter and ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-455-2260 ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... 16, 2013 With its fingerprint-identity sensor, Apple,s new ... mobile devices.  Unfortunately, it didn,t take long for hackers ... 5S, but software from an upstate New ... – safeguards users, devices against such vulnerabilities. ...
... NEW YORK , Oct. 17, 2013 /PRNewswire-iReach/ -- ... and personalized medicine, is pleased to announce the deployment of ... based on its proprietary cloud-based biomedical engine, Cliniscan ... Cliniscan TM , the ...
... Babcock Genetics, Inc., a worldwide supplier of swine genetics, announces ... genetic program available to swine producers. "Babcock ... offer a higher level of profitability to our customers." said ... are maximizing genetic improvement by selecting lines that best complement ...
Cached Biology News:NexID Biometrics: The Solution to Spoofing Mobile Biometrics 2NexID Biometrics: The Solution to Spoofing Mobile Biometrics 3Picofemto Deploys Cloud-Based Cliniscan EEG Analytics and Clinical Decision Support 2Picofemto Deploys Cloud-Based Cliniscan EEG Analytics and Clinical Decision Support 3
8.1.1...
Human SCP3 Affinity Purified Polyclonal Ab Keywords: Spermatogenesis, meiosis Protein Family: Cell Cycle...
... and efficient purification of DNA and oligonucleotides ... by gravity flow.Prepacked with Sephadex G-25 DNA ... CG/ICP Biocide.Available in three sizes depending on ... ml (NAP-10) or 2.5 ml (NAP-25).Useful for ...
Homo sapiens alcohol dehydrogenase 5 (class III), chi polypeptide (ADH5), mRNA....
Biology Products: